FILE:AMGN/AMGN-8K-20111130122654.txt.gz
EVENTS:	Other Events
TEXT:
ITEM: Other Events
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
 
 
 
 
 
On November 30, 2011, Amgen Inc. (the "Company") priced an offering of 550,000,000 aggregate principal amount of Senior Notes due 2018 (the "2018 Notes") and 475,000,000 aggregate principal amount of Senior Notes due 2026 (the "2026 Notes," and together with the 2018 Notes, the "Notes"). The Notes are being sold outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended (the "Securities Act"). The Notes have not been and will not be registered under the Securities Act and may not be offered or sold within the United States. Interest on the 2018 Notes will be paid in cash annually in arrears at rate of 4.375% per annum, and interest on the 2026 Notes will be paid in cash annually in arrears at rate of 5.50% per annum. The Notes will be issued pursuant to an indenture, dated as of August 4, 2003, between the Company and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, and an officers' certificate setting forth the terms of the Notes. Settlement for the offering is expected to occur on December 5, 2011, subject to the execution of a subscription agreement for the Notes and the satisfaction of customary closing conditions.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 


